Skin biomarkers for neurodegenerative disease: a future perspective.
Juan Pablo Castanedo-Cazares, Idelfonso Rodriguez-Leyva
https://pubmed.ncbi.nlm.nih.gov/26619251/Actively Recruiting
Led by Universidad Autonoma de San Luis Potosí · Updated on 2024-12-16
40
Participants Needed
1
Research Sites
1 weeks
Total Duration
Researchers are studying how certain proteins that clump together in the brain, such as alpha-synuclein, amyloid-beta, phosphorylated tau, and TDP-43, appear in skin samples from people with neurodegenerative diseases like Alzheimers, frontotemporal dementia, Parkinsons disease, atypical Parkinsonism, amyotrophic lateral sclerosis, and normal pressure hydrocephalus. The study compares these protein patterns in skin biopsies between patients with these diseases, those with normal pressure hydrocephalus, and healthy individuals without neurodegenerative conditions. This observational study collects skin biopsies from participants to analyze the presence and pattern of these protein clumps using immunohistochemistry and immunofluorescence techniques. Participants are grouped into those with neurodegenerative diseases, those with normal pressure hydrocephalus, and healthy controls matched by age but without personal or family history of neurodegenerative disorders. The analysis aims to identify specific patterns that differentiate these groups. Participants will be recruited and evaluated during a single visit lasting about one hour, during which the skin biopsy is taken. The researchers will then analyze the samples and compare the protein aggregation patterns, a process expected to take up to two years for final reporting. The study involves detailed clinical evaluation and follows strict inclusion and exclusion criteria to ensure reliable comparisons across groups.
CONDITIONS
Proteinopathies Expression in Skin of Neurodegenerative Disorders
I
Ildefonso Rodríguez-Leyva, MD PhD
C
Cristina Monzón Tapia, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Universidad Autonoma de San Luis Potosí
Lead Sponsor
Hospital Central "Dr. Ignacio Morones Prieto"
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Same day
Participants undergo skin biopsies which are analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated proteins associated with neurodegenerative diseases.
1 visit (in-person)
Duration - Up to 2 years
Participants are observed for outcomes related to protein aggregation patterns based on their biopsy results over an extended period.
No additional visits required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Juan Pablo Castanedo-Cazares, Idelfonso Rodriguez-Leyva
https://pubmed.ncbi.nlm.nih.gov/26619251/Alberto J Espay, Gustavo A Da Prat, Alok K Dwivedi...
https://pubmed.ncbi.nlm.nih.gov/28892572/Todd E Golde, David R Borchelt, Benoit I Giasson...
https://pubmed.ncbi.nlm.nih.gov/23635781/Ildefonso Rodríguez-Leyva, Erika G Chi-Ahumada, Juan Carrizales...
https://pubmed.ncbi.nlm.nih.gov/27042679/Harun Muayad Said, Derya Kaya, Idil Yavuz...
https://pubmed.ncbi.nlm.nih.gov/35431542/Universidad Autonoma de San Luis Potosí
Lead Sponsor
Hospital Central "Dr. Ignacio Morones Prieto"
Collaborating Sponsor